(Q37099019)

18 August 2017

1 reference

title

Doxazosin in the current treatment of hypertension (English)

1 reference

18 August 2017

Andrzej Wykretowicz

1

0 references

Przemysław Guzik

object named as

Przemyslaw Guzik

series ordinal

2

0 references

author name string

Henryk Wysocki

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

625-633

1 reference

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Doxazosin GITS versus standard doxazosin in mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Alpha1-adrenergic blockers: current usage considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Controlled-release doxazosin as combination therapy in hypertension: the GATES study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Clinical ease of using doxazosin in BPH patients with and without hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Drug delivery systems for treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The Japan Morning Surge-1 (JMS-1) study: protocol description.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

A new era in hypertension research: discussing the findings of ALLHAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Comments on ALLHAT and doxazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

ASCOT: a tale of two treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Outcome beyond blood pressure control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Old drug, new tricks: the unexpected effect of doxazosin on high-density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.625

21 January 2018

Identifiers

DOI

10.1517/14656566.9.4.625

1 reference

18 August 2017

1 reference